Association of the British Pharmaceutical Industry (ABPI) and the AHSN Network
today announce a new, five-year partnership to accelerate the introduction and uptake
of transformative biomedical innovations into the NHS.
terms of the new partnership, a process will be created where AHSNs and ABPI
member companies can identify and collaborate on projects to accelerate the
spread of proven innovation in the NHS.
collaborative projects will address the new national priority areas of the 15
AHSNs. These include:
and artificial intelligence
and personalised medicine
and medicines optimisation.
agreements at regional level and for specific disease areas have already
demonstrated positive results. For example, the Greater Manchester
Pharmaceutical Industry Partnership has resulted in the progression of three
substantial projects in Hepatitis C, COPD and mental health in its first year
of operation. All of these projects have matched health system needs with
Thompson, Chief Executive of the ABPI said:
“As a result
of this new partnership, patients will be able to benefit from the innovative
medicines and technologies of the future faster and more consistently.
delighted to be working with the AHSN Network on this important initiative.
for success will be a virtuous circle that delivers benefits for patients and
the NHS. There will also be economic benefits to the UK from a thriving life
Mike Hannay, Chair of the AHSN Network said:
excited about the opportunities afforded by our new partnership with the ABPI,
with whom we already have a long-standing and very positive relationship.
Network is committed to creating the right environment for industry to work
with the health and social care system. The establishment of the Innovation
Exchange model, commissioned by the Office for Life Sciences, provides a step
change opportunity to re-engineer a more effective industry interface.
together with the ABPI partnership, will enable companies to benefit from a
consistent offering from whichever AHSN they interact with. In turn, the NHS
will benefit from better identification of products and services that can
benefit patients and the health system, as well as improved signposting to
relevant agencies and programmes where not directly provided by AHSNs.”
Network and the Association of British Healthcare Industries (ABHI) have
also formalised closer working arrangements.
Read more here.